Back to List View Graph View

Glucagon-like peptide-1 agonist

Glucagon-like peptide-1 receptor agonists (GLP-1 RAS, also called incretin mimetics) are a class of injectable and oral drug therapies used to treat type 2 diabetes and obesity.

Where the papers sit

79 papers from the last 6 months study glucagon-like peptide-1 agonist directly · updated from PubMed 15 Nov 2026

  • GLP-1 Safety and Outcomes

    GLP-1RA treatment is being evaluated across cardiovascular, neurologic, psychiatric, cancer, fracture, pulmonary, and postoperative outcomes in diabetes and obesity. Observational cohorts generally suggest favorable cardiovascular outcomes and possible protection against dementia and complications, but associations vary by disease and comparator. Studies also examine atrial fibrillation, pancreatic cancer, hematologic malignancy, lymphedema, and alcohol-related hospitalization. Residual confounding and the need for long-term safety surveillance remain central limitations.

    21 papers · 26.6%

  • Weight-Loss Treatment and Care

    GLP-1-based therapy is shifting from weight loss alone toward long-term weight management supported by lifestyle care, rehabilitation, and follow-up. Semaglutide and tirzepatide dominate comparisons, while new long-acting agents and oral approaches aim to widen access and reduce treatment burden. Discontinuation, post-bariatric weight regain, body-composition changes, and treatment costs repeatedly limit durable benefit. Telehealth support, clinician attitudes, adherence, and cosmetic concerns increasingly shape outcomes after prescribing.

    17 papers · 21.5%

  • Diabetes Drug Comparisons

    GLP-1RAs are being positioned alongside SGLT2 inhibitors, DPP-4 inhibitors, and sulfonylureas for comparative effectiveness, safety, and cost in type 2 diabetes. Recurring endpoints include survival, nephropathy, cancer, gastrointestinal motility, hair loss, osteoarthritis, treatment escalation, and affordability. Health-system studies increasingly weigh real-world uptake and return on investment rather than glycemic control alone. Drug delivery and DPP-4 degradation represent parallel efforts to improve peptide treatment and pharmacology.

    13 papers · 16.5%

  • GLP-1 in Special Populations

    GLP-1RA use is expanding into adolescents, transplant recipients, cystic-fibrosis diabetes, Cushing syndrome, obstructive sleep apnea, and patients with pancreatic lesions. Liraglutide and oral nonpeptide agonists are being assessed for weight and metabolic benefits, while pulmonary and cardiovascular effects broaden the therapeutic rationale. Safety questions recur around neuropsychiatric events, vagal activity, malignancy, and delayed gastric emptying before anesthesia. Digital support and prescribing outside approved indications reflect the challenge of sustaining treatment in diverse populations.

    13 papers · 16.5%

  • Incretins in Metabolic Liver Disease

    Incretin therapies are moving toward metabolic dysfunction-associated steatotic liver disease and steatohepatitis, with biochemical, imaging, inflammation, and fibrosis outcomes under study. Dulaglutide and broader mono- to multi-agonist strategies support the search for liver benefits beyond glucose and weight control. Mechanistic work links gut-pancreatic signaling to feeding cognition, insulin action, and β-cell regeneration. Whether these approaches prevent fibrosis progression or metastatic disease, and how best to measure tissue response, remains unresolved.

    8 papers · 10.1%

  • Real-World GLP-1 Outcomes

    GLP-1RA use is moving into broader real-world care for obesity and diabetes, including children and patients after bariatric surgery. Studies report weight-related benefits alongside changes in inflammation, anemia, and kidney outcomes. Tirzepatide is being used for recurrent post-bariatric weight gain, while health-care costs remain compared with metabolic surgery. Heterogeneous treatment effects and patient safety concerns keep long-term selection and monitoring open.

    7 papers · 8.9%

NEW DIRECTION

Semaglutide becomes cargo for a patient-administered transdermal delivery system rather than only a conventionally administered metabolic therapy

Cargo-aware dissolving microneedles for semaglutide treat the glucagon-like peptide-1 receptor agonist as a peptide cargo to be delivered through skin, rather than as a drug whose clinical effects are evaluated after conventional administration. The optimized microneedle achieved 90.58% relative bioavailability compared with subcutaneous delivery, introducing a patch-based route intended to replace weekly injections and changing the practical delivery model for the agent. 42764083Sep

Papers

The 79 papers from the last 6 months that study glucagon-like peptide-1 agonist directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

GLP-1 Safety and Outcomes (21)
  1. GLP-1 receptor agonist use in patients with minor stroke is associated with lower risk of post-stroke dementia. Journal of neurology · 7 Nov 2026 PMID 42998120
  2. GLP-1 therapies and cancer risk. Science (New York, N.Y.) · 5 Nov 2026 PMID 42986942
  3. Glucagon-like peptide-1 receptor agonist use and risk of postmastectomy lymphedema in breast cancer survivors: a multicenter real-world cohort study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 27 Oct 2026 PMID 42934302
  4. Long-Term Association Between GLP-1 Receptor Agonist Use and Incident Pancreatic Cancer: A Propensity Score-Matched Retrospective Cohort Study Using the TriNetX Network. Journal of gastrointestinal cancer · 16 Sept 2026 PMID 42745130
  5. GLP-1 receptor agonists vs DPP-4 inhibitors and neuropathic complications in type 2 diabetes. Journal of neurology · 7 Sept 2026 PMID 42704495
  6. Association of GLP1-Receptor Agonists With Diabetic Retinopathy. Diabetes, obesity & metabolism · 27 Aug 2026 PMID 42660856
  7. Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study. PloS one · 24 Aug 2026 PMID 42636218
  8. Antihyperglycemic Drugs and Risk of Asthma Exacerbation in Patients With Asthma and Type 2 Diabetes: A Multinational Retrospective Cohort Study. Pharmacotherapy · 19 Aug 2026 PMID 42618217
  9. GLP-1RAs Use and Postoperative Outcomes in T2DM Patients Undergoing Radical Nephrectomy. Clinical genitourinary cancer · 18 Aug 2026 PMID 42613293
  10. Association of GLP-1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real-World Claims Database Study. Diabetes, obesity & metabolism · 12 Aug 2026 PMID 42581431
  11. Association between glucagon-like peptide-1 receptor agonist use and ischemic stroke severity. Journal of the neurological sciences · 23 Jul 2026 PMID 42492143
  12. Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study. BMJ open · 21 Jul 2026 PMID 42481079
  13. Glucagon-like peptide-1 receptor agonists and new-onset atrial fibrillation in adults with diabetes or obesity: a multinational cohort study. Diabetes research and clinical practice · 21 Jul 2026 PMID 42480717
  14. Association of GLP1-Receptor Agonists With Risk of Hematologic Malignancies in People With Diabetes. Clinical lymphoma, myeloma & leukemia · 18 Jul 2026 PMID 42471299
  15. Association of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study. The lancet. Psychiatry · 15 Jul 2026 PMID 42456704
  16. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study. Diabetes, obesity & metabolism · 30 Jun 2026 PMID 42380063
  17. GLP-1 receptor agonists and clinical outcomes in adults with Crohn's disease and obesity: a propensity score-matched real-world cohort study. Scientific reports · 19 Jun 2026 PMID 42321339
  18. Glucagon-like peptide-1 receptor agonist use for type 2 diabetes and risk of upper extremity fragility fracture. Injury · 18 Jun 2026 PMID 42314528
  19. GLP-1 Receptor Agonists and Primary Prevention of Cancer Therapy-Related Cardiac Dysfunction. The American journal of cardiology · 9 Jun 2026 PMID 42264283
  20. GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 29 May 2026 PMID 42210885
  21. GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated Lp(a) levels: A Multicenter retrospective study. International journal of cardiology · 27 May 2026 PMID 42203003
Weight-Loss Treatment and Care (17)
  1. GLP-1 receptor agonist-associated weight loss in breast cancer patients receiving concurrent endocrine therapy: a retrospective cohort analysis. Breast cancer research and treatment · 26 Oct 2026 PMID 42932003
  2. GLP-1 receptor agonist initiation and risk of psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes in the USA: an observational cohort study using electronic health records data. The lancet. Psychiatry · 14 Oct 2026 PMID 42874603
  3. Adjuvant Glucagon-Like Peptide-1 Receptor Agonist Therapy Post-Bariatric Surgery: An Exploratory Single-Institution Analysis. The Journal of surgical research · 21 Sept 2026 PMID 42767161
  4. Cargo-aware design of dissolving microneedles: an FEA-guided rational framework reveals distinct delivery mechanisms for small and large molecules. International journal of pharmaceutics · 20 Sept 2026 PMID 42764083
  5. Efficacy and safety of glucagon-like peptide-1 receptor agonists for diabetic cardiomyopathy: a protocol for systematic review and meta-analysis. BMJ open · 25 Aug 2026 PMID 42642087
  6. Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes. Diabetes research and clinical practice · 10 Aug 2026 PMID 42575344
  7. Perceived Competence and GLP-1RA Weight Management Engagement: Mixed-Methods Insights From Six Patient Groups. Obesity (Silver Spring, Md.) · 10 Aug 2026 PMID 42572911
  8. Attitudes of Swedish primary care physicians toward GLP-1 receptor agonists for overweight and obesity: a cross-sectional survey. BMC primary care · 6 Aug 2026 PMID 42557543
  9. First-in-Human Study of a Long-Acting GLP-1 Receptor Agonist (TE-8105) in Overweight or Obese Adults Without Type 2 Diabetes Mellitus. Journal of clinical pharmacology · 30 Jul 2026 PMID 42530137
  10. Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey. Journal of managed care & specialty pharmacy · 27 Jul 2026 PMID 42504813
  11. GLP-1 receptor agonists in kidney transplant recipients with post-transplant diabetes: efficacy and safety outcomes from a retrospective cohort study. Archives of endocrinology and metabolism · 22 Jul 2026 PMID 42485571
  12. Combining GLP-1 Receptor Agonists and Health-Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real-World Single-Center Study. Pediatric obesity · 1 Jun 2026 PMID 42222894
  13. Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 29 May 2026 PMID 42210883
  14. After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care. Journal of medical Internet research · 28 May 2026 PMID 42206886
  15. Hemodynamic and metabolomic responses to infusion of GLP-1 agonist exenatide in pulmonary arterial hypertension. JCI insight · 22 May 2026 PMID 42171611
  16. ICER report demonstrates both the value and challenges in financing of weight loss medications. Journal of managed care & specialty pharmacy · 21 May 2026 PMID 42166309
  17. Body composition changes in patients on GLP-1 receptor agonists undergoing an intensive cardiac rehabilitation program. European journal of preventive cardiology · 21 May 2026 PMID 42165511
Diabetes Drug Comparisons (13)
  1. Return on investment of SGLT2 inhibitors and GLP-1 receptor agonists: Implications of real-world use for managed care. Journal of managed care & specialty pharmacy · 29 Sept 2026 PMID 42808548
  2. Trends in utilization of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and metabolic bariatric surgery in U.S. adults with diabetes and obesity. Diabetes research and clinical practice · 20 Aug 2026 PMID 42624330
  3. Association of GLP-1 receptor agonists, SGLT 2 inhibitors, DPP-4 inhibitors, and sulfonylureas with incident cancer in type 2 diabetes. Diabetes research and clinical practice · 17 Aug 2026 PMID 42607727
  4. Bioinspired pullulan-based adhesive coacervate films for targeted buccal delivery of peptides. Carbohydrate polymers · 12 Aug 2026 PMID 42586641
  5. Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second-Line Antidiabetic Drugs. Diabetes, obesity & metabolism · 7 Aug 2026 PMID 42563367
  6. Availability, treatment costs and affordability of SGLT-2 inhibitors and GLP-1 RAs for diabetes in 10 countries: a cross-sectional study. BMJ open · 24 Jul 2026 PMID 42498467
  7. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ (Clinical research ed.) · 22 Jul 2026 PMID 42486607
  8. Comparative effects of SGLT2 inhibitors and GLP-1 receptor agonists on osteoarthritis risk in patients with type 2 diabetes mellitus: A multi-institutional cohort study. PloS one · 20 Jul 2026 PMID 42475344
  9. GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Diabetic Nephropathy: A Comparative Study. Saudi medical journal · 14 Jul 2026 PMID 42445750
  10. PROTAC-Mediated DPP-4 Degradation: A New Solution for Type 2 Diabetes. Journal of medicinal chemistry · 8 Jun 2026 PMID 42260272
  11. Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study. Diabetes, obesity & metabolism · 5 Jun 2026 PMID 42244136
  12. Survival association of GLP-1 receptor agonists and SGLT2 inhibitors in bladder cancer patients. Urologic oncology · 1 Jun 2026 PMID 42224918
  13. Comprehensive drug safety assessment of sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors: A Danish population-based active comparator new user cohort study. Diabetes research and clinical practice · 27 May 2026 PMID 42202888
GLP-1 in Special Populations (13)
  1. Neuropsychiatric Outcomes Associated With GLP-1 Receptor Agonist Use in Medicare Beneficiaries With Type 2 Diabetes: Variation by Treatment Pattern and Obesity Status. Diabetes, obesity & metabolism · 26 Oct 2026 PMID 42928425
  2. Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication. Obesity (Silver Spring, Md.) · 22 Sept 2026 PMID 42768905
  3. A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan. Obesity research & clinical practice · 15 Sept 2026 PMID 42744726
  4. Impact of GLP-1 receptor agonists on patients with intraductal papillary mucinous neoplasms: Study protocol for a multicentric cohort study. PloS one · 9 Sept 2026 PMID 42715243
  5. Delayed gastric emptying in adolescent patients on glucagon-like peptide-1 receptor agonists with standard preoperative fasting guidelines: a prospective cohort study. British journal of anaesthesia · 8 Sept 2026 PMID 42711215
  6. Vagal activity-related events and glucagon-like peptide-1 receptor agonists. European heart journal. Cardiovascular pharmacotherapy · 8 Sept 2026 PMID 42709513
  7. Digital Behavioral Infrastructure for Glucagon-Like Peptide-1 Pharmacotherapy: Viewpoint on Persistence, Tolerability, and Postcessation Durability. Journal of medical Internet research · 8 Sept 2026 PMID 42709474
  8. Pulmonary response to glucagon-like peptide-1 receptor agonist therapy in adults with cystic fibrosis-related diabetes: factors associated with improvement in FEV1. Respiratory medicine · 2 Sept 2026 PMID 42685881
  9. Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial. Signal transduction and targeted therapy · 13 Aug 2026 PMID 42595749
  10. Glucagon-like peptide-1 receptor agonist prevents pulmonary fibrosis following acute COVID-19 infection associated with type 2 diabetes. Journal of virology · 9 Jul 2026 PMID 42423377
  11. Glucagon-like peptide receptor agonists (GLP-1RAs) as cardiovascular risk modifiers in obstructive sleep apnea and obesity: a real-world study. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 1 Jul 2026 PMID 42387223
  12. Impact of Glucagon-Like Peptide-1 Agonist Use on Weight Trajectory and Clinical Outcomes Following Liver Transplantation. Transplantation proceedings · 8 Jun 2026 PMID 42259739
  13. Glucagon-like peptide-1 receptor agonist exposure and malignancy risk in patients with endogenous Cushing's syndrome. The Journal of clinical endocrinology and metabolism · 3 Jun 2026 PMID 42233686
Incretins in Metabolic Liver Disease (8)
  1. Glucagon-like peptide-1 receptor agonist dulaglutide attenuates liver injury in metabolic dysfunction-associated steatotic liver disease with diabetic mice. European journal of pharmacology · 17 Aug 2026 PMID 42607855
  2. Guideline on treatment intensification with injectable therapies beyond GLP-1 RA based therapies in type 2 diabetes. Diabetes research and clinical practice · 2 Aug 2026 PMID 42543082
  3. AI digital pathology as a key tool providing in-depth understanding of the progression and regression of MASH and fibrosis in male mouse models. Nature communications · 22 Jul 2026 PMID 42486853
  4. Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction-associated steatotic liver disease. American journal of preventive cardiology · 3 Jul 2026 PMID 42395062
  5. The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies. Bioscience reports · 17 Jun 2026 PMID 42307179
  6. Lentiviral GLP-1 gene therapy elicits developmental stage-dependent β-cell regeneration in diabetic rats. Journal of molecular medicine (Berlin, Germany) · 11 Jun 2026 PMID 42277427
  7. Associations of PYY, GLP-1 and LEAP2 with changes in feeding-related cognition, body weight and glucose homeostasis after bariatric surgery in non-diabetic women. Journal of neuroendocrinology · 29 May 2026 PMID 42210737
  8. GLP-1 RAs May Prevent Metastatic Progression. Cancer discovery · 23 May 2026 PMID 42175743
Real-World GLP-1 Outcomes (7)
  1. Real-world Evidence for Improvements in Inflammation and Anemia Biomarkers After the Initiation of GLP-1RA in Patients Receiving Hemodialysis. Kidney medicine · 25 Sept 2026 PMID 42787930
  2. Trends in GLP-1 Receptor Agonist Prescriptions for Children Ages 8 to 11 With Obesity: 2019-2026. Pediatrics · 3 Sept 2026 PMID 42692477
  3. Metabolic effects of GLP-1 receptor agonists in rheumatology patients and inflammatory outcomes: a single-centre retrospective cohort. RMD open · 25 Aug 2026 PMID 42642078
  4. Patient Experiences and Safety Concerns Regarding GLP-1 Receptor Agonists for Obesity: A Cross-Sectional Survey in Jeddah, Saudi Arabia. Saudi medical journal · 14 Aug 2026 PMID 42598160
  5. Heterogeneous treatment effects of GLP-1RA on kidney outcomes in patients with type 2 diabetes. Kidney international · 24 Jul 2026 PMID 42498061
  6. Long-Term Health Care Utilization Costs of GLP-1RA Use vs Bariatric Metabolic Surgery. JAMA network open · 1 Jul 2026 PMID 42384380
  7. Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety. Obesity surgery · 5 Jun 2026 PMID 42247124

By study type

Clinical trials (3)
  1. Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial. Signal transduction and targeted therapy · 13 Aug 2026 PMID 42595749
  2. First-in-Human Study of a Long-Acting GLP-1 Receptor Agonist (TE-8105) in Overweight or Obese Adults Without Type 2 Diabetes Mellitus. Journal of clinical pharmacology · 30 Jul 2026 PMID 42530137
  3. Associations of PYY, GLP-1 and LEAP2 with changes in feeding-related cognition, body weight and glucose homeostasis after bariatric surgery in non-diabetic women. Journal of neuroendocrinology · 29 May 2026 PMID 42210737
Observational studies and case reports (40)
  1. GLP-1 receptor agonist use in patients with minor stroke is associated with lower risk of post-stroke dementia. Journal of neurology · 7 Nov 2026 PMID 42998120
  2. Glucagon-like peptide-1 receptor agonist use and risk of postmastectomy lymphedema in breast cancer survivors: a multicenter real-world cohort study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 27 Oct 2026 PMID 42934302
  3. GLP-1 receptor agonist-associated weight loss in breast cancer patients receiving concurrent endocrine therapy: a retrospective cohort analysis. Breast cancer research and treatment · 26 Oct 2026 PMID 42932003
  4. GLP-1 receptor agonist initiation and risk of psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes in the USA: an observational cohort study using electronic health records data. The lancet. Psychiatry · 14 Oct 2026 PMID 42874603
  5. Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication. Obesity (Silver Spring, Md.) · 22 Sept 2026 PMID 42768905
  6. Adjuvant Glucagon-Like Peptide-1 Receptor Agonist Therapy Post-Bariatric Surgery: An Exploratory Single-Institution Analysis. The Journal of surgical research · 21 Sept 2026 PMID 42767161
  7. Long-Term Association Between GLP-1 Receptor Agonist Use and Incident Pancreatic Cancer: A Propensity Score-Matched Retrospective Cohort Study Using the TriNetX Network. Journal of gastrointestinal cancer · 16 Sept 2026 PMID 42745130
  8. Impact of GLP-1 receptor agonists on patients with intraductal papillary mucinous neoplasms: Study protocol for a multicentric cohort study. PloS one · 9 Sept 2026 PMID 42715243
  9. Delayed gastric emptying in adolescent patients on glucagon-like peptide-1 receptor agonists with standard preoperative fasting guidelines: a prospective cohort study. British journal of anaesthesia · 8 Sept 2026 PMID 42711215
  10. Vagal activity-related events and glucagon-like peptide-1 receptor agonists. European heart journal. Cardiovascular pharmacotherapy · 8 Sept 2026 PMID 42709513
  11. Trends in GLP-1 Receptor Agonist Prescriptions for Children Ages 8 to 11 With Obesity: 2019-2026. Pediatrics · 3 Sept 2026 PMID 42692477
  12. Pulmonary response to glucagon-like peptide-1 receptor agonist therapy in adults with cystic fibrosis-related diabetes: factors associated with improvement in FEV1. Respiratory medicine · 2 Sept 2026 PMID 42685881
  13. Association of GLP1-Receptor Agonists With Diabetic Retinopathy. Diabetes, obesity & metabolism · 27 Aug 2026 PMID 42660856
  14. Metabolic effects of GLP-1 receptor agonists in rheumatology patients and inflammatory outcomes: a single-centre retrospective cohort. RMD open · 25 Aug 2026 PMID 42642078
  15. Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study. PloS one · 24 Aug 2026 PMID 42636218
  16. Trends in utilization of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and metabolic bariatric surgery in U.S. adults with diabetes and obesity. Diabetes research and clinical practice · 20 Aug 2026 PMID 42624330
  17. Antihyperglycemic Drugs and Risk of Asthma Exacerbation in Patients With Asthma and Type 2 Diabetes: A Multinational Retrospective Cohort Study. Pharmacotherapy · 19 Aug 2026 PMID 42618217
  18. GLP-1RAs Use and Postoperative Outcomes in T2DM Patients Undergoing Radical Nephrectomy. Clinical genitourinary cancer · 18 Aug 2026 PMID 42613293
  19. Patient Experiences and Safety Concerns Regarding GLP-1 Receptor Agonists for Obesity: A Cross-Sectional Survey in Jeddah, Saudi Arabia. Saudi medical journal · 14 Aug 2026 PMID 42598160
  20. Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes. Diabetes research and clinical practice · 10 Aug 2026 PMID 42575344
  21. Attitudes of Swedish primary care physicians toward GLP-1 receptor agonists for overweight and obesity: a cross-sectional survey. BMC primary care · 6 Aug 2026 PMID 42557543
  22. Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey. Journal of managed care & specialty pharmacy · 27 Jul 2026 PMID 42504813
  23. Availability, treatment costs and affordability of SGLT-2 inhibitors and GLP-1 RAs for diabetes in 10 countries: a cross-sectional study. BMJ open · 24 Jul 2026 PMID 42498467
  24. Association between glucagon-like peptide-1 receptor agonist use and ischemic stroke severity. Journal of the neurological sciences · 23 Jul 2026 PMID 42492143
  25. GLP-1 receptor agonists in kidney transplant recipients with post-transplant diabetes: efficacy and safety outcomes from a retrospective cohort study. Archives of endocrinology and metabolism · 22 Jul 2026 PMID 42485571
  26. Glucagon-like peptide-1 receptor agonists and new-onset atrial fibrillation in adults with diabetes or obesity: a multinational cohort study. Diabetes research and clinical practice · 21 Jul 2026 PMID 42480717
  27. Comparative effects of SGLT2 inhibitors and GLP-1 receptor agonists on osteoarthritis risk in patients with type 2 diabetes mellitus: A multi-institutional cohort study. PloS one · 20 Jul 2026 PMID 42475344
  28. Association of GLP1-Receptor Agonists With Risk of Hematologic Malignancies in People With Diabetes. Clinical lymphoma, myeloma & leukemia · 18 Jul 2026 PMID 42471299
  29. Association of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study. The lancet. Psychiatry · 15 Jul 2026 PMID 42456704
  30. GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Diabetic Nephropathy: A Comparative Study. Saudi medical journal · 14 Jul 2026 PMID 42445750
  31. Long-Term Health Care Utilization Costs of GLP-1RA Use vs Bariatric Metabolic Surgery. JAMA network open · 1 Jul 2026 PMID 42384380
  32. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study. Diabetes, obesity & metabolism · 30 Jun 2026 PMID 42380063
  33. Glucagon-like peptide-1 receptor agonist use for type 2 diabetes and risk of upper extremity fragility fracture. Injury · 18 Jun 2026 PMID 42314528
  34. GLP-1 Receptor Agonists and Primary Prevention of Cancer Therapy-Related Cardiac Dysfunction. The American journal of cardiology · 9 Jun 2026 PMID 42264283
  35. Glucagon-like peptide-1 receptor agonist exposure and malignancy risk in patients with endogenous Cushing's syndrome. The Journal of clinical endocrinology and metabolism · 3 Jun 2026 PMID 42233686
  36. Combining GLP-1 Receptor Agonists and Health-Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real-World Single-Center Study. Pediatric obesity · 1 Jun 2026 PMID 42222894
  37. GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 29 May 2026 PMID 42210885
  38. GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated Lp(a) levels: A Multicenter retrospective study. International journal of cardiology · 27 May 2026 PMID 42203003
  39. Comprehensive drug safety assessment of sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors: A Danish population-based active comparator new user cohort study. Diabetes research and clinical practice · 27 May 2026 PMID 42202888
  40. Body composition changes in patients on GLP-1 receptor agonists undergoing an intensive cardiac rehabilitation program. European journal of preventive cardiology · 21 May 2026 PMID 42165511
Human data, design not indexed (16)
  1. GLP-1 therapies and cancer risk. Science (New York, N.Y.) · 5 Nov 2026 PMID 42986942
  2. Return on investment of SGLT2 inhibitors and GLP-1 receptor agonists: Implications of real-world use for managed care. Journal of managed care & specialty pharmacy · 29 Sept 2026 PMID 42808548
  3. Digital Behavioral Infrastructure for Glucagon-Like Peptide-1 Pharmacotherapy: Viewpoint on Persistence, Tolerability, and Postcessation Durability. Journal of medical Internet research · 8 Sept 2026 PMID 42709474
  4. GLP-1 receptor agonists vs DPP-4 inhibitors and neuropathic complications in type 2 diabetes. Journal of neurology · 7 Sept 2026 PMID 42704495
  5. Efficacy and safety of glucagon-like peptide-1 receptor agonists for diabetic cardiomyopathy: a protocol for systematic review and meta-analysis. BMJ open · 25 Aug 2026 PMID 42642087
  6. Association of GLP-1 receptor agonists, SGLT 2 inhibitors, DPP-4 inhibitors, and sulfonylureas with incident cancer in type 2 diabetes. Diabetes research and clinical practice · 17 Aug 2026 PMID 42607727
  7. Perceived Competence and GLP-1RA Weight Management Engagement: Mixed-Methods Insights From Six Patient Groups. Obesity (Silver Spring, Md.) · 10 Aug 2026 PMID 42572911
  8. Guideline on treatment intensification with injectable therapies beyond GLP-1 RA based therapies in type 2 diabetes. Diabetes research and clinical practice · 2 Aug 2026 PMID 42543082
  9. Heterogeneous treatment effects of GLP-1RA on kidney outcomes in patients with type 2 diabetes. Kidney international · 24 Jul 2026 PMID 42498061
  10. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ (Clinical research ed.) · 22 Jul 2026 PMID 42486607
  11. Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study. BMJ open · 21 Jul 2026 PMID 42481079
  12. Glucagon-like peptide receptor agonists (GLP-1RAs) as cardiovascular risk modifiers in obstructive sleep apnea and obesity: a real-world study. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 1 Jul 2026 PMID 42387223
  13. Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 29 May 2026 PMID 42210883
  14. After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care. Journal of medical Internet research · 28 May 2026 PMID 42206886
  15. GLP-1 RAs May Prevent Metastatic Progression. Cancer discovery · 23 May 2026 PMID 42175743
  16. ICER report demonstrates both the value and challenges in financing of weight loss medications. Journal of managed care & specialty pharmacy · 21 May 2026 PMID 42166309
Preclinical: animal, cell and lab studies (7)
  1. Cargo-aware design of dissolving microneedles: an FEA-guided rational framework reveals distinct delivery mechanisms for small and large molecules. International journal of pharmaceutics · 20 Sept 2026 PMID 42764083
  2. Glucagon-like peptide-1 receptor agonist dulaglutide attenuates liver injury in metabolic dysfunction-associated steatotic liver disease with diabetic mice. European journal of pharmacology · 17 Aug 2026 PMID 42607855
  3. Bioinspired pullulan-based adhesive coacervate films for targeted buccal delivery of peptides. Carbohydrate polymers · 12 Aug 2026 PMID 42586641
  4. AI digital pathology as a key tool providing in-depth understanding of the progression and regression of MASH and fibrosis in male mouse models. Nature communications · 22 Jul 2026 PMID 42486853
  5. Glucagon-like peptide-1 receptor agonist prevents pulmonary fibrosis following acute COVID-19 infection associated with type 2 diabetes. Journal of virology · 9 Jul 2026 PMID 42423377
  6. Lentiviral GLP-1 gene therapy elicits developmental stage-dependent β-cell regeneration in diabetic rats. Journal of molecular medicine (Berlin, Germany) · 11 Jun 2026 PMID 42277427
  7. Hemodynamic and metabolomic responses to infusion of GLP-1 agonist exenatide in pulmonary arterial hypertension. JCI insight · 22 May 2026 PMID 42171611
Unclassified: not yet indexed with MeSH (13)
  1. Neuropsychiatric Outcomes Associated With GLP-1 Receptor Agonist Use in Medicare Beneficiaries With Type 2 Diabetes: Variation by Treatment Pattern and Obesity Status. Diabetes, obesity & metabolism · 26 Oct 2026 PMID 42928425
  2. Real-world Evidence for Improvements in Inflammation and Anemia Biomarkers After the Initiation of GLP-1RA in Patients Receiving Hemodialysis. Kidney medicine · 25 Sept 2026 PMID 42787930
  3. A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan. Obesity research & clinical practice · 15 Sept 2026 PMID 42744726
  4. Association of GLP-1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real-World Claims Database Study. Diabetes, obesity & metabolism · 12 Aug 2026 PMID 42581431
  5. Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second-Line Antidiabetic Drugs. Diabetes, obesity & metabolism · 7 Aug 2026 PMID 42563367
  6. Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction-associated steatotic liver disease. American journal of preventive cardiology · 3 Jul 2026 PMID 42395062
  7. GLP-1 receptor agonists and clinical outcomes in adults with Crohn's disease and obesity: a propensity score-matched real-world cohort study. Scientific reports · 19 Jun 2026 PMID 42321339
  8. The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies. Bioscience reports · 17 Jun 2026 PMID 42307179
  9. PROTAC-Mediated DPP-4 Degradation: A New Solution for Type 2 Diabetes. Journal of medicinal chemistry · 8 Jun 2026 PMID 42260272
  10. Impact of Glucagon-Like Peptide-1 Agonist Use on Weight Trajectory and Clinical Outcomes Following Liver Transplantation. Transplantation proceedings · 8 Jun 2026 PMID 42259739
  11. Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety. Obesity surgery · 5 Jun 2026 PMID 42247124
  12. Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study. Diabetes, obesity & metabolism · 5 Jun 2026 PMID 42244136
  13. Survival association of GLP-1 receptor agonists and SGLT2 inhibitors in bladder cancer patients. Urologic oncology · 1 Jun 2026 PMID 42224918